Futura Medical Regulatory News (FUM)

9 May 2007 07:02

Futura Medical PLC09 May 2007 For immediate release 9 May 2007 Futura Medical Plc ("Futura" or "the Company") CSD500 patents granted in 30 countries Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovativeproducts for consumer healthcare, announces that, in the run-up to thecommercial launch of its novel condom CSD500, patents have been granted, or areproceeding to grant, in 30 consumer markets including the principal territorieswithin Europe, the US and Canada. Futura has submitted patent applications internationally to protect its uniqueintellectual property in a total of 38 countries and expects to receive patentgrants in all of these countries in due course. CSD500, which will be marketed by SSL International plc (SSL) as a Durex(R)branded condom, contains an erectogenic gel known as Zanifil(R) which will helphealthy men maintain a firm erection whilst wearing the condom. Futura and SSLare currently preparing for the market launch of CSD500 which will follow theanticipated marketing authorisation within the EU in the fourth quarter of 2007.Futura will receive a milestone payment once marketing authorisation for CSD500is granted within the EU, and royalty based payments from future sales of thecondom. James Barder, Futura Medical's Chief Executive, said: "We are delighted with theprogress we have made with our patent applications as IP protection willunderpin our revenue streams from CSD500 following the commercial launch of theproduct by our marketing partner SSL." For further information:Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Canaccord Adams Tel: +44 (0) 20 7050 6500Mark AshurstTyler Broda Media enquiries:Buchanan CommunicationsMark Court / Rebecca Dietrich Tel: +44 (0) 020 7466 5000 Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forconsumer healthcare. The Company is developing a portfolio of products and itsstrategy is to license their manufacture and distribution to majorpharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange